An interventional study of GERONTE in Breast Cancer, Comorbidities and Coexisting Conditions and Lung Cancer, sponsored by Institut Bergonié. Active, not recruiting at 11 sites in France. Open to participants aged 70 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Institut Bergonié · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Breast Neoplasms by Institut Bergonié — 4 open to participants now, 6 under way, none of them phase 3. Breast Neoplasms · Institut Bergonié.
Among the 29 studies in Breast Neoplasms by Institut Bergonié, this one is the 3rd largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2024, is one of 16 with no phase, and was the 27th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 29 studies in Breast Neoplasms by Institut Bergonié are open now, in 1 country. Recruiting first, the newest first:
Institut Bergonié · Sites in France
Ages 15–49
Institut Bergonié · Sites in France
Ages 18+ · Women only
Institut Bergonié · Sites in France
Ages 18+ · Women only
Institut Bergonié
Ages 18–50 · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 70 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 2
First in 1990; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 720 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 87 across the 20 interventional studies, 149 across the 8 observational. Of the 18 that completed or were terminated, 14 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
Institut Bergonié is the lead sponsor of 119 studies on the registry; 16 are open to participants now.
1 of the studies in Breast Neoplasms by Institut Bergonié that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07425548Institut BergoniéEvaluation of Quality of Life After Facial Hyaluroic Acid Injections Following Treatment for Breast Cancer. | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Breast Neoplasms by Institut Bergonié, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of GERONTE STUDY is to evaluate the effectiveness of the GERONTE, ICT-based, integrated care pathway to improve patient 6-month quality of life, in France.
Study design is a stepped wedge randomised controlled trial. Clusters will be participating hospitals, comprising eight investigating sites in total (Figure 2).
This is a stepped wedge of cross-over type. Patients included at each "step" are different individuals. The first "step" is a reference measurement where none of the clusters will implement the intervention. The investigating sites will be randomly drawn to determine the order in which they will implement the intervention, by "steps" of two months.
The primary endpoint is the Quality of Life assessed by the EORTC QLQ-C30 (version 3.0) questionnaire at 6 months after GERONTE implementation. It has 3 sub-scores that will be analysed independently, with alpha risk adjustment.
This is a stepped wedge of cross-over type. Patients included at each "step" are different individuals. The first "step" is a reference measurement where none of the clusters will implement the intervention. The investigating sites will be randomly drawn to determine the order in which they will implement the intervention, by "steps" of two months. A total of 10 patients by step are to be included in each center; these 10 patients must be regularly included along the 2-month period of each step. If 10 patients are already included before the end of the 2 months' step period, the center has to stop the inclusions till the beginning of the subsequent step. If a center, near to the end of a step, is far from reaching of the 10 patients' inclusion, it must increase the speed of its inclusions to be as close as possible of 10 patients included at the end of the step. In each center, patient sample has to be representative of type of cancer managed in the center, along the trial duration. The repartition of cancer types must be homogeneous along the steps and during the trial duration.
All participating investigating sites will have study collaborators in charge of organizing intervention implementation and data collection. The intervention will be prepared prior to the start of the trial, so that each investigating site can implement it as defined by the randomisation. Each center engaged to participate needs to participate till the end of the trial. A center commitment to participate will be requested before each center involvement to avoid center withdrawal after the start of the trial. Quantitative data regarding the myPatientSpace adapted for GERONTE app usage will be collected at each step and in each cluster by study collaborators, from the beginning of GERONTE system implementation. Care outcome data (Quality of life, anxiety, autonomy, additional hospitalisation, mortality...) will be collected by local referents at 3, 6, 9 and 12 months after inclusion in GERONTE. The data necessary to calculate the real cost of the intervention, of its implementation and of resource use data of patient management will be continuously collected during follow-up. GERONTE patient-centered system implementation and usage will be collected by the local referents in each center. Qualitative analysis will be performed in each center at GERONTE system implementation and during follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
- General inclusion criteria
Patients affiliated with a French social security scheme in accordance with the French law on biomedical research (Article 1121-11 of the French Code of Public health).
Tumor specific inclusion criteria
Specific inclusion criteria for breast cancer:
9.1. Non- breast cancer (M0):
- No prior treatment for the current breast cancer.
- All 3 criteria required:
o Clinical staging: cT2-3-4 Nany, or cTany N1-2-3;
The cancer specialist considers* radiotherapy and/or chemotherapy. 9.2. Metastatic breast cancer (M1): Both criteria required:
The patient received maximum 1 for metastatic disease.
Specific inclusion criteria for colorectal cancer:
10.1. Non-metastatic colorectal cancer (M0):
- No prior therapy for the current tumor in the recruiting hospital
At least one of the 3 criteria required:
o The cancer specialist considers* surgery;
The cancer specialist considers* first or second line systemic therapy and/or radiotherapy (+/- surgery). No previous chemotherapy allowed except /perioperative chemotherapy stopped for more than 12 months.
11.1. Non-metastatic lung cancer (M0):
At least one of the 3 criteria required:
11.2. Metastatic lung cancer (M1):
The cancer specialist considers* first or second line systemic therapy. Possible systemic therapies are chemotherapy and/or immune therapy and/or targeted therapy. Patients only considered* for monotherapy with anti-EGFR TKI or somatostatin analog are not eligible.
*'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
12. Specific inclusion criteria for prostate cancer: 12.1. Non-metastatic prostate cancer (M0): one of the following:
First diagnosis M0 prostate cancer (no therapy received yet for prostate cancer): at least one of the 2 criteria required:
o The cancer specialist considers* radiotherapy;
o The cancer specialist considers* hormone therapy (ADT +/- combination Abiraterone and Prednisone).
Salvage treatment M0 prostate cancer (received prior surgery at least 6 months before):
o The cancer specialist considers* radiotherapy (+/- ADT)
Non-metastatic castration resistant prostate cancer:
12.2. Metastatic prostate cancer (M1): - The cancer specialist considers* treatment with Abiraterone or Enzalutamide or Apalutamide, or Docetaxel or Cabazitaxel or PARP-inhibitors or Lutetium PSMA.
*'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway;
Other: GERONTE
Patients included in the control arm will be managed according to the standard of care.
The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway
Quality of life assessed by the EORTC quality of life questionnaire (EORTC QLQ-C30 )
Quality of life assessed by the quality of life questionnaire (EORTC QLQ-C30) questionnaire at 6 months after inclusion: * Normalised global health status score * Normalised score of the physical functioning scale * Normalised score of the emotional functioning scale the minimum value of the EORTC QLQ-C30 is 30 and the maximum value is 126, and higher scores mean a worse result.
Time frame: 6 months
Quality of life of elders cancer patients
Scores of the quality of life questionnaire for elderly cancer patients.(QLQ-ELD14). The minimum value is 14 and the maximum value is 40, and higher scores mean a worse result.
Time frame: baseline 3, 9 and 12 months
Quality of life by the EORTC quality of life questionnaire (EORTC QLQ-C30 )
The quality of life questionnaire (QLQ-C30) scores. The minimum value of the EORTC QLQ-C30 is 30 and the maximum value is 126, and higher scores mean a worse result.
Time frame: baseline 3, 9 and 12 months
Survival
Overall survival and progression-free survival
Time frame: at 12 months
Patient frailty
Score of the Clinical frailty scale
Time frame: baseline, 3, 6, 9 and 12 months
Patient autonomy,
Dependence score of the Activities of Daily Living scale (ADL); Proportion of patients living at home; Number of completed chair stands in 30 seconds
Time frame: baseline, 3, 6, 9 and 12 months
Patient weight evolution
Weight in Kilograms
Time frame: baseline, 3, 6, 9 and 12 months
Patient anxiety
Score of Hospital Anxiety and Depression (HAD) scale. The minimum value is 0 and the maximum value is 21, and higher scores mean a worse result.
Time frame: baseline, 3, 6, 9 and 12 months
institutionalisation
Proportion of patient institutionalised per participants
Time frame: 6 and 12 months
unscheduled hospitalisations
Proportion of unscheduled hospitalisations per participants
Time frame: 6 and 12 months
Cost per life years gained
using utility assessed through normalised scores of EQ-5D-5L questionnaire
Time frame: baseline, 3, 6, 9 and 12 months
Caregiver burden in health, psychological well-being, finances, social life and relationship with patient
Zarit Burden Interview
Time frame: baseline, 3, 6, 9 and 12 months
Patient experience of person-centered coordinated care
Person-Centered Coordinated Care Experience Questionnaire (P3CEQ)The minimum value is 0 and the maximum value is 45, and higher scores mean a better result.
Time frame: 6 and 12 months
Patient, physician and health-professionals-reported overall satisfaction with the IC technology of the GERONTE system
Score derived from the mHealth App Usability Questionnaire (MAUQ) for standalone mHealth Apps using the Patient version for patient satisfaction and the provider version for physician and health-professional.The minimum value is 0 and the maximum value is 126, and higher scores mean a better result.
Time frame: 6 and 12 months
GERONTE patient-centered system implementation and usage
use of the myPatientSpace adapted for GERONTE app measures, for instance: number and frequency of connections.
Time frame: 6 months
Ran from Oct 2024 to primary completion in Nov 2026, 24 months.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's 24 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.